BridgeBio Pharma (FRA:2CL) Tariff Resilience Score: 7/10 (As of Jul. 02, 2026)


FRA:2CL BridgeBio Pharma Inc FRA:2CL
67 GF Score
Price €64.57
GF Value €124.84
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is BridgeBio Pharma Tariff Resilience Score?

BridgeBio Pharma FRA:2CL +0.80% 67 Tariff Resilience Score is 7 as of Jul. 02, 2026. GuruFocus rates FRA:2CL with a GF Score™ of 67/100 and a GF Value™ of €124.84 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 1,374 Biotechnology companies, BridgeBio Pharma ranks better than 90.39% on this metric.

BridgeBio Pharma has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

BridgeBio Pharma has BridgeBio Pharma's focus on pharmaceuticals means it has some exposure to global supply chains for raw materials. However, its primary market is the U.S., and it benefits from industry-specific exemptions. The company has alternative suppliers and some pricing power to mitigate tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes BridgeBio Pharma might have Highly Resilient.

BridgeBio Pharma  (FRA:2CL) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

BridgeBio Pharma Tariff Resilience Score Related Terms

FRA:2CL vs EXEL, IONS, JAZZ: Tariff Resilience Score Comparison

For the Biotechnology subindustry, BridgeBio Pharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Pharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Tariff Resilience Score falls into.


FRA:2CL
67GF Score
BridgeBio Pharma Inc FRA:2CL
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
BridgeBio Pharma (FRA:2CL) has a Tariff Resilience Score of 7 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, BridgeBio Pharma ranks #132 out of 1374 companies in the Biotechnology industry, placing it in the top 9.6%.
Is BridgeBio Pharma's Tariff Resilience Score too high?
BridgeBio Pharma's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. BridgeBio Pharma's value of 7 is 75% above this industry median. Based on the distribution chart, BridgeBio Pharma ranks #132 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BridgeBio Pharma has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Tariff Resilience Score compare to EXEL and IONS?
According to the Biotechnology industry distribution chart, BridgeBio Pharma ranks #132 out of 1374 companies for Tariff Resilience Score. This places BridgeBio Pharma in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. BridgeBio Pharma's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BridgeBio Pharma's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Pharma's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €124.84, compared to a current price of €64.57 — trading 48.3% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. BridgeBio Pharma's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Tariff Resilience Score is 7 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €64.57 is trading 48.3% below its estimated GF Value™ of €124.84. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

  • Tariff Resilience Score: 7
  • GF Value™: €124.84 vs. price of €64.57 (48.3% below fair value)
  • GF Score™: 67/100 with 8 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1374)

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BridgeBio Pharma Business Description

Other Exchanges BBIO:USA1BBIO:Italy
Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
67GF Score

Get the complete analysis for FRA:2CL

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€64.57
Price
€124.84
GF Value